The latest data from an ongoing early cancer detection study based on ITUS Corporation’s proprietary Cchek? technology, will be presented at the annual meeting of the American Association of Cancer Research (AACR) to be held in Chicago, Illinois, April 14-18, 2018, and will be attended by world leading experts across the field of cancer research. Later in the year, an additional presentation will be made at the annual meeting of the American Association of Immunologists (AAI) in Austin, Texas. The meeting will be held May 4-8, 2018 will be attended by physicians and scientists dedicated to understanding and advancing the field of immunology.
The proprietary Cchek technology combines immunophenotyping, or analysis of white blood cells, with artificial intelligence (AI) to detect the presence of solid tumor from a blood sample.? ITUS utilizes flow cytometry for immunophenotyping by monitoring leukocytes (white blood cells) focusing on a recently discovered class of cells known as Myeloid Derived Suppressor Cells (MDSCs).
These cells, as well as other myeloid and lymphoid cells, comprise the human immune system, and ITUS’s Cchek? monitors perturbations in the immune system to identify tumors.? An Artificial Intelligence application known as a Neural Network is utilized to perform the analysis.
|Video: Changing Strategies in the ?War on Cancer? – Part 1: Early Diagnosis – The New Paradigm -? an interview with Amit Kumar, Ph.D, President and CEO of ITUS Corporation.|
“We are pleased that our presentation was accepted for these conferences, as our focus is on monitoring the immune system to catch cancer early, and this audience is focused on immunology.? Blood bathes all organs of the body, and within it are the signals that indicate disease.? For early cancer detection it has been hard to identify those signals because they are so rare.? With our flow cytometry protocols coupled with Artificial Intelligence, we have demonstrated an excellent ability to identify the signals that distinguish tumor-bearing patients from healthy individuals,” noted Amit Kumar, Ph.D, President and CEO of ITUS Corporation.
Earlier this year ITUS Corporation and Serametrix Corporation signed an agreement to combine the power of ITUS’ Cchek with Serametrix’s substantial expertise in immune monitoring assays.? Today, flow cytometry and related data analysis services are offered by Serametrix. The company, which is partly owned by the Ludwig Institute for Cancer Research (LICR), provides solutions to the problem of monitoring immune response to immunotherapies in clinical trial cancer patients.
“There is potential for tremendous synergy from the complementary expertise of ITUS and Serametrix. ?We believe that the additional capabilities provided by the Serametrix alliance will allow ITUS Corporation to expand the commercial opportunities of Cchek,” Kumar explained.
“Also, we believe that the application of our artificial intelligence expertise to Serametrix’s flow cytometry immuno-profiling services will allow Serametrix to offer unique and superior capabilities unavailable to other laboratories,” Kumar continued,
“As we develop our early cancer detection diagnostic, we expect this collaboration will create additional exposure of our technology to potential corporate partners.”
“We are delighted to enter into this agreement with ITUS as our respective technologies and capabilities are highly complementary.? In particular, we believe that the application of ITUS artificial intelligence will add value to our unique and proprietary MDSC monitoring technology and we are looking forward to exploring novel opportunities with our extensive network of academic and commercial partners,” Henry Hepburne-Scott, VP of Business Development of Serametrix, said.
Last Editorial Review: March 16, 2018
Featured Image: Medical/science laboratory test tubes. Courtesy: ? 2010 – 2018 Fotolia. Used with permission.
Copyright ? 2010 – 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.